Welcome to our dedicated page for Butterfly Network news (Ticker: BFLY), a resource for investors and traders seeking the latest updates and insights on Butterfly Network stock.
Butterfly Network, Inc. (BFLY) is revolutionizing the healthcare landscape with its innovative digital health solutions, primarily focused on handheld, whole-body ultrasound technology. The company, which operates at the nexus of advanced engineering and scientific disciplines, has assembled a team of world-class talents in computer science, physics, and electrical engineering. Underpinned by a robust financial foundation from a select group of highly successful serial entrepreneurs, Butterfly Network is uniquely positioned to dedicate its full attention to product and intellectual property development.
Butterfly Network's flagship product, the Butterfly iQ+, represents a significant leap in medical imaging technology. This compact, user-friendly device leverages the company's proprietary Ultrasound-on-Chip technology to enable healthcare professionals to perform comprehensive whole-body imaging using a single handheld probe. The device's affordability and portability make it a game-changer in clinical settings, ensuring that high-quality ultrasound imaging is accessible and practical for a wide range of medical applications.
The integration of cloud-connected software with hardware technology further enhances the utility of the Butterfly iQ+, allowing for seamless data acquisition and analysis via a mobile application. This connectivity facilitates the practical application of ultrasound information within clinical workflows, thereby improving diagnostic capabilities and patient outcomes.
Recent achievements and ongoing projects include advancements in ultrasound technology and the expansion of the product's applications in various medical fields. The company's commitment to innovation is reflected in its continuous efforts to enhance the performance and capabilities of its devices.
With a strong focus on R&D and a strategic approach to technological development, Butterfly Network is poised to make significant contributions to digital health and medical imaging. The company's progress and updates can be closely followed through the latest news and press releases, which provide valuable insights into its performance, events, and developments.
Butterfly Network Inc. (NYSE: BFLY) has launched its third-generation handheld point-of-care ultrasound system, Butterfly iQ3™, in Europe. The device, built on advanced Ultrasound-on-Chip™ technology, offers improved image quality, new 3D imaging capabilities, and a smaller, lighter design. Key features include:
1. Unparalleled image quality with twice the processing power of its predecessor
2. Novel tools: iQ Slice™ and iQ Fan™ for advanced 3D imaging
3. Ergonomic design: 17% smaller probe face, 7% shorter probe, and 2.5x faster charging
4. CE marked and EU MDR certified
The Butterfly iQ3 is now available in 16 European countries, expanding the company's mission to democratize ultrasound technology.
Butterfly Network (NYSE: BFLY), a digital health company specializing in handheld, whole-body ultrasound and intuitive software, has announced its participation in Lake Street Capital Markets' 8th Annual Best Ideas Growth Conference. The event is scheduled for September 12, 2024, in New York City.
Heather Getz, Chief Financial and Operations Officer at Butterfly Network, will be representing the company in one-on-one investor meetings during the conference. This participation provides an opportunity for Butterfly Network to showcase its innovative technology and growth potential to investors.
Interested parties can schedule meetings with Heather Getz through their Lake Street representatives, offering a chance for in-depth discussions about the company's future prospects and strategies.
Butterfly Network (NYSE: BFLY) has appointed Steve Cashman as Chief Business Officer, effective immediately. Cashman, a seasoned healthcare leader, joins the company following its successful launch of the third-generation Butterfly iQ3 and record revenue performance in H1 2024. He will oversee global sales, marketing, product, and corporate strategy as part of the Executive Management Team.
Cashman brings extensive health technology expertise and commercial leadership, having previously served as CEO of Caption Health and CCO at InTouch Health. His appointment follows Butterfly's announcement of its highest quarterly revenue in Q2, reaching $21.5 million, a 16% year-over-year growth. This achievement underscores the growing demand for Butterfly's innovative ultrasound technology and the effectiveness of its strategy.
Butterfly Network (NYSE: BFLY), a digital health company specializing in handheld, whole-body ultrasound and intuitive software, has announced its participation in TD Cowen's 9th Annual FutureHealth Conference on September 10, 2024 in New York City. Nevada Sanchez, Co-Founder & Vice President of Core Technology at Butterfly Network, will be part of a panel discussion titled 'AI in the Healthcare Ecosystem' from 3:15 pm to 4:00 pm ET.
The panel will be an in-person event without virtual streaming options. Interested parties can contact their TD Cowen representative for more information or to schedule meetings with Butterfly Network management during the conference.
Avive Solutions, Inc., a manufacturer of innovative Automated External Defibrillators (AEDs) and software solutions, has appointed Katerina Miras as their Vice President of Marketing. Miras, with extensive experience in medtech, brings expertise in creating healthcare brands that accelerate commercial growth. She previously held leadership roles at Medivis and Butterfly Network (NYSE: BFLY), where she contributed to significant market share growth and brand recognition.
As VP of Marketing, Miras will focus on enhancing Avive's brand identity, driving awareness, and leading the company's marketing strategy in the AED and cardiac arrest response space. Her vision includes increasing the presence of Avive's AEDs in key markets and championing the company's mission to improve Sudden Cardiac Arrest outcomes through faster, more connected care.
Butterfly Network (NYSE: BFLY) reported its Q2 2024 financial results, highlighting record quarterly revenue of $21.5 million, representing 16% YoY growth. The company reduced its net loss by 45% and net cash used in operations by 62% YoY.
Key achievements include the launch of the iQ3 in Canada, expansion into Southeast Asia, and success with the medical school Campus Essentials program. Butterfly also made significant strides in AI and technology with new development partnerships.
Financial highlights include a gross profit of $12.6 million and operating expenses down by 29% YoY. The company improved its adjusted EBITDA guidance and regained compliance with NYSE listing standards.
Butterfly Network (NYSE: BFLY) has announced it will report its second quarter 2024 financial results on August 1, 2024, after market close. The company, known for its portable ultrasound technology, will host a conference call and webcast at 5:00 pm ET on the same day. Joseph DeVivo, President, CEO, and Chairman, along with Heather Getz, EVP and CFO, will lead the discussion on financial results and operational progress.
The call will be broadcast live via webcast on Butterfly's Investor Relations website. Interested parties can also dial in to listen. A replay of the call will be available until August 15, 2024. This announcement indicates Butterfly's commitment to transparency and shareholder communication, providing investors with an opportunity to gain insights into the company's performance and future outlook.
On June 27, 2024, UltraSight announced its partnership with Butterfly Network to integrate real-time AI guidance into Butterfly's handheld ultrasound devices. This collaboration aims to improve access to cardiac care by enabling more healthcare professionals to perform cardiac ultrasounds, addressing the global shortage of sonographers and reducing delays in cardiac testing. Cardiovascular disease is the leading cause of death worldwide, and this initiative seeks to empower even novice users to conduct echocardiographic exams. With regulatory approvals, UltraSight's AI software will be deployed on Butterfly's platform to enhance diagnostic accuracy and accessibility. This partnership follows Butterfly's recent launch of the Butterfly Garden AI Marketplace in August 2023, opening its platform to third-party developers.
HeartFocus has joined the Butterfly Garden AI Marketplace by Butterfly Network, aiming to integrate its AI-powered heart scan software with Butterfly's handheld ultrasound system. This collaboration plans to release the software after necessary approvals, enabling healthcare professionals to conduct cardiac scans anytime, anywhere.
The initiative leverages Butterfly's extensive imaging platform and HeartFocus' proprietary algorithms trained on over 10 million data points. The goal is to enhance access to precision cardiac care and improve cardiovascular disease detection and management.
Butterfly Network's SDK and APIs allow third-party developers to create AI applications, expanding the usability of its ultrasound technology. This partnership could significantly democratize access to high-quality cardiovascular care globally.
Butterfly Network (NYSE: BFLY), a digital health company specializing in handheld, whole-body ultrasound devices and software, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference.
Joseph DeVivo, the company's President, CEO, and Chairman, will present and hold one-on-one investor meetings. The presentation is scheduled for June 12, 2024, at 10:00 am ET in Miami, Florida.
A live webcast will be available on Butterfly's investor website, with replays accessible post-event.
FAQ
What is the current stock price of Butterfly Network (BFLY)?
What is the market cap of Butterfly Network (BFLY)?
What is Butterfly Network, Inc.?
What product does Butterfly Network offer?
How does the Butterfly iQ+ work?
What makes Butterfly Network's technology unique?
Who funds Butterfly Network?
What are the recent achievements of Butterfly Network?
How does Butterfly Network contribute to healthcare?
Is Butterfly Network publicly traded?
Can the Butterfly iQ+ be used in multiple medical settings?
Where can I find the latest news on Butterfly Network?
